All In Biotech

Drug Trial Radar · NCT04940741

Efficacy and Safety of VER-01 in the Treatment of Patients With Chronic Non-specific Low Back Pain

Proof of Efficacy, Maintenance of Efficacy, Long-term Safety and Investigation of the Potential for Dependence and Abuse and the Effect of Abrupt Drug Withdrawal of VER-01 in the Treatment of Patients With Chronic Non-specific Low Back Pain

Last checked: Nov 19, 2026Latest source record: Apr 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 820 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

820

Actual

Start

Jul 7, 2021

Primary completion

Mar 26, 2024

Study completion Mar 26, 2024

Sponsor

Lead sponsor
Vertanical GmbHIndustry
Sponsor type
Industry
First posted
Jun 28, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Analysis of the efficacy, maintenance of efficacy, long-term safety, and investigation of the potential for dependence and abuse and the effect of abrupt drug withdrawal of VER-01 in the treatment of patients with chronic non-specific low back pain when drug treatment is indicated and previous optimised treatments with non-opioid analgesics have not led to sufficient pain relief or were unsuitable due to contraindications or intolerance.

Conditions

  • Chronic Non-specific Low Back Pain

Interventions

  • VER-01Drug

    standardised cannabis extract (containing 21 mg THC per gram drug product)

  • PlaceboOther

    comparator without active ingredient

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase A: Efficacy based on pain reductionTime frame: Baseline up to 15 weeks
  2. Phase B: Safety based on occurrence of treatment-related AEs/SAEsTime frame: Up to 29 weeks
  3. Phase C: Safety based on occurrence of treatment-related AEs/SAEsTime frame: Up to 28 weeks
  4. Phase D: Maintenance of efficacyTime frame: Up to 4 weeks (from date of randomization R2 until the first day of treatment failure)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Emovis GmbH

    Berlin, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.